Quest Diagnostics Inc.
3 Giralda Farms
599 articles with Quest Diagnostics Inc.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced the pricing of a public offering of $500 million aggregate principal amount of its 4.200% senior notes due 2029 under the Quest Diagnostics' shelf registration statement.
Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results; Provides Guidance For Full Year 2019
Fourth quarter diluted EPS of $0.92 on a reported basis, down 49.5% from 2017 which included a tax benefit recorded as a result of the Tax Cuts and Jobs Act (TCJA); and $1.36 on an adjusted basis excluding amortization, down 2.9% from 2017
Quest Diagnostics Incorporated announced that it will report fourth quarter and full year 2018 results on Thursday, February 14, 2019, before the market opens
Quest Diagnostics, a Pioneer in Consumer Health, Expands Offering with Launch of QuestDirect, a Service that Provides Consumers Access to Lab Testing without Visiting a Doctor's Office
QuestDirect Builds on Quest's existing consumer offerings available through the new and improved MyQuest patient platform that lets people access their lab results, schedule appointments and pay bills
Quest Diagnostics Incorporated announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City.
Second quarter revenues of $1.92 billion, up 3.0% from 2017
Quest Diagnostics Incorporated announced that it will report second quarter 2018 results on Tuesday, July 24, 2018
Quest Diagnostics Incorporated announced that it is scheduled to speak at the William Blair 38th Annual Growth Stock Conference in Chicago.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Helen I. Torley was elected to serve as a director at the company's 2018 Annual Meeting of Stockholders, expanding the Board of Directors to 10 members.
Quest Diagnostics Incorporated announced today financial results for the first quarter ended March 31, 2018.
Quest Diagnostics Inc. announced that it will report first quarter 2018 results on Thursday, April 19, 2018.
Quest Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Guidance For Full Year 2018
Quest Diagnostics announced today financial results for the fourth quarter and full year ended December 31, 2017.
Transaction expands Quest’s scale and reach in the mobile provider segment and bolsters its extended care capabilities.
Quest Diagnostics to Acquire MedXM, Expanding its Health Risk Assessment Services to Close Gaps in Care
The acquisition will expand Quest's scale and reach in the mobile/home segment and bolster its overall capabilities in extended care.
Quest Diagnostics announced that it will report fourth quarter and full year 2017 results on Thursday, February 1, 2018, before the market opens.
Quest Diagnostics today announced it has completed its previously announced acquisition of the Shiel Medical Laboratory business from Fresenius Medical Care, the premier healthcare company focused on delivering the highest quality care to people with renal and other chronic conditions.
Quest Diagnostics Supports Suit Against HHS Charging That CMS Ignored Congressional Intent in Implementing New Clinical Lab Payment System
The lawsuit by ACLA asserts that CMS, operating under the purview of HHS, ignored congressional intent and instituted a highly flawed data reporting process in advance of setting market rates under the PAMA.
Quest Diagnostics Completes Acquisition of Cleveland HeartLab and Formalizes R&D Collaboration With Cleveland Clinic
Quest will establish a national center of excellence focused on heart disease diagnostics within Cleveland HeartLab's existing 25,000 square-foot clinical laboratory facility in Cleveland.
Quest Diagnostics the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.45 per share, payable on January 24, 2018 to shareholders of record of Quest Diagnostics common stock on January 9, 2018.